Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by FormerHedgieon Sep 23, 2024 5:39pm
135 Views
Post# 36237245

The acquisition of Tibelia is strategically important

The acquisition of Tibelia is strategically important I was quite happy to see the announcement of Tibelia by RX.  While there wasn't nearly enough financial information to determine the present value impact on Tibelia to RX what it did indicate is the companies desire to spend the accumulated profits (cash) to acquire new products / jurisdictions that will help to grow revenue / profits but more importantly, will help to diversify the companies products as well as add some geographic diversification.  I really like to see this.

Add this into the Zofenopril announcement and I believe that RX is on course to begin to show some meaningful revenue growth and increased profitability leading to strong cash flow generation.

I believe that these new products and the growth that they represent, will lead to renewed interest in RX as a higher growth company that should attract more investors and likely result in improving valuation metrics. 

I had come close to selling my shares recently, however, I have seen some important changes coming from management that have renewed my interest in the prospects of RX for the short and long-term so I will continue to retain my position in the company.

Keep it up Rene / RX, I like what you are doing.

<< Previous
Bullboard Posts
Next >>